Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Bladder Cancer, July 2021

Free Subscription


Abstracts

Retrieve all available abstracts of the following 208 articles:
HTML format


 

Single Articles

  1. LIU X, Li H, Che N, Zheng Y, et al
    HBXIP accelerates glycolysis and promotes cancer angiogenesis via AKT/mTOR pathway in bladder cancer.
    Exp Mol Pathol. 2021 Jun 30:104665. doi: 10.1016/j.yexmp.2021.104665.
    PubMed    
    Abstract available

  2. BARON P, Khene Z, Lannes F, Pignot G, et al
    Multicenter external validation of the radical cystectomy pentafecta in a European cohort of patients undergoing robot-assisted radical cystectomy with intracorporeal urinary diversion for bladder cancer.
    World J Urol. 2021 Jul 3. pii: 10.1007/s00345-021-03753.
    PubMed    
    Abstract available

  3. NAGAKAWA S, Shiota M, Fujimoto N, Yamamoto Y, et al
    The impact of single-nucleotide polymorphisms on intravesical recurrence after bacillus Calmette-Guerin therapy for non-muscle invasive bladder cancer in a genome-wide association study.
    Urol Oncol. 2021 Jun 29. pii: S1078-1439(21)00254.
    PubMed    
    Abstract available

  4. MIRANDA AF, Howard JM, McLaughlin M, Meng X, et al
    Metastasis-directed radiation therapy after radical cystectomy for bladder cancer.
    Urol Oncol. 2021 Jun 29. pii: S1078-1439(21)00212.
    PubMed    
    Abstract available

  5. KAGAWA M, Kawakami S, Yamamoto A, Suzuki O, et al
    Identification of Lynch syndrome-associated DNA mismatch repair-deficient bladder cancer in a Japanese hospital-based population.
    Int J Clin Oncol. 2021 Jul 2. pii: 10.1007/s10147-021-01922.
    PubMed    
    Abstract available

  6. LU J, Luo JH, Pang J, Cao JZ, et al
    [Corrigendum] Lentivirusmediated RNA interference of clusterin enhances the chemosensitivity of EJ bladder cancer cells to epirubicin in vitro.
    Mol Med Rep. 2021;24.
    PubMed    
    Abstract available

  7. BLOMQVIST M, Koskinen I, Loyttyniemi E, Mirtti T, et al
    Prognostic and predictive value of ALDH1, SOX2 and SSEA-4 in bladder cancer.
    Sci Rep. 2021;11:13684.
    PubMed    
    Abstract available

  8. WANG Y, Wu J, Luo W, Zhang H, et al
    ALPK2 acts as tumor promotor in development of bladder cancer through targeting DEPDC1A.
    Cell Death Dis. 2021;12:661.
    PubMed    
    Abstract available

  9. ELDH M, Mints M, Hiltbrunner S, Ladjevardi S, et al
    Proteomic Profiling of Tissue Exosomes Indicates Continuous Release of Malignant Exosomes in Urinary Bladder Cancer Patients, Even with Pathologically Undetectable Tumour.
    Cancers (Basel). 2021;13.
    PubMed    
    Abstract available

  10. SIKIC D, Taubert H, Wirtz RM, Breyer J, et al
    High Androgen Receptor mRNA Expression Is Associated with Improved Outcome in Patients with High-Risk Non-Muscle-Invasive Bladder Cancer.
    Life (Basel). 2021;11.
    PubMed    
    Abstract available

  11. CHIEN TM, Wu KH, Chuang YT, Yeh YC, et al
    Withaferin A Triggers Apoptosis and DNA Damage in Bladder Cancer J82 Cells through Oxidative Stress.
    Antioxidants (Basel). 2021;10.
    PubMed    
    Abstract available

  12. WANG P, Zhou R, Thomas P, Zhao L, et al
    Epithelial-to-Mesenchymal Transition Enhances Cancer Cell Sensitivity to Cytotoxic Effects of Cold Atmospheric Plasmas in Breast and Bladder Cancer Systems.
    Cancers (Basel). 2021;13.
    PubMed    
    Abstract available

  13. ZHANG C, Berndt-Paetz M, Neuhaus J
    A Comprehensive Bioinformatics Analysis of Notch Pathways in Bladder Cancer.
    Cancers (Basel). 2021;13.
    PubMed    
    Abstract available

  14. KOLAT D, Kaluzinska Z, Bednarek AK, Pluciennik E, et al
    WWOX Loses the Ability to Regulate Oncogenic AP-2gamma and Synergizes with Tumor Suppressor AP-2alpha in High-Grade Bladder Cancer.
    Cancers (Basel). 2021;13.
    PubMed    
    Abstract available

  15. RINALDI F, Maurizi L, Forte J, Marazzato M, et al
    Resveratrol-Loaded Nanoemulsions: In Vitro Activity on Human T24 Bladder Cancer Cells.
    Nanomaterials (Basel). 2021;11.
    PubMed    
    Abstract available

  16. SURMAN M, Kedracka-Krok S, Jankowska U, Drozdz A, et al
    Proteomic Profiling of Ectosomes Derived from Paired Urothelial Bladder Cancer and Normal Cells Reveals the Presence of Biologically-Relevant Molecules.
    Int J Mol Sci. 2021;22.
    PubMed    
    Abstract available

  17. BOTTA C, Agostino RM, Dattola V, Cianci V, et al
    Myositis/Myasthenia after Pembrolizumab in a Bladder Cancer Patient with an Autoimmunity-Associated HLA: Immune-Biological Evaluation and Case Report.
    Int J Mol Sci. 2021;22.
    PubMed    
    Abstract available

  18. CHUNG DY, Kang DH, Kim JW, Ha JS, et al
    Comparison of Oncologic Outcomes of Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin (ddMVAC) with Gemcitabine and Cisplatin (GC) as Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer: Systematic Review and Meta-Analysis.
    Cancers (Basel). 2021;13.
    PubMed    
    Abstract available

  19. CLAPS F, van de Kamp MW, Mayr R, Bostrom PJ, et al
    Risk factors associated with positive surgical margins' location at radical cystectomy and their impact on bladder cancer survival.
    World J Urol. 2021 Jul 1. pii: 10.1007/s00345-021-03776.
    PubMed    
    Abstract available

  20. XIA QD, Hu J, Liu Z, Li C, et al
    Sex differences resulted differential morbidity and mortality in bladder cancer: smoke, hormone or urobiome?
    World J Urol. 2021 Jul 1. pii: 10.1007/s00345-021-03775.
    PubMed    


  21. WANG W, Ying Y, Xie H, Li J, et al
    miR-665 inhibits epithelial-to-mesenchymal transition in bladder cancer via the SMAD3/SNAIL axis.
    Cell Cycle. 2021 Jul 1:1-12. doi: 10.1080/15384101.2021.1929677.
    PubMed    
    Abstract available

  22. ANZELA A, Min M, Knesl M, Buddle N, et al
    Concurrent carbogen and nicotinamide with radiation therapy in muscle invasive bladder cancer: A report on feasibility in the Australian setting.
    J Med Imaging Radiat Oncol. 2021 Jun 30. doi: 10.1111/1754-9485.13265.
    PubMed    
    Abstract available

  23. SMITH L, Carrie A, Tully M, Barnett Y, et al
    The CADENCE pilot trial - Promoting physical activity in bladder cancer survivors: A protocol paper.
    Contemp Clin Trials Commun. 2021;22:100809.
    PubMed    
    Abstract available


  24. Adjuvant Immunotherapy Best for ctDNA(+) Bladder Cancer.
    Cancer Discov. 2021 Jun 30. pii: 2159-8290.CD-NB2021-0365.
    PubMed    
    Abstract available

  25. PETRYLAK DP, Powles T, Rosenberg JE
    Enfortumab Vedotin in Advanced Urothelial Carcinoma. Reply.
    N Engl J Med. 2021;385:93-94.
    PubMed    


  26. YEON SH, Lee HJ
    Enfortumab Vedotin in Advanced Urothelial Carcinoma.
    N Engl J Med. 2021;385:93.
    PubMed    


  27. YAKOVLEV PG, Gorbach OI, Ostapchenko LI, Garmanchuk LV, et al
    Expression of TLR4 and major inflammatory cytokines in patients with bladder cancer of different grade and stage.
    Exp Oncol. 2021;43:142-148.
    PubMed    
    Abstract available

  28. SUH J, Jung JH, Kwak C, Kim HH, et al
    Stratifying risk for multiple, recurrent, and large (>/=3 cm) Ta, G1/G2 tumors in non-muscle-invasive bladder cancer.
    Investig Clin Urol. 2021;62:408-415.
    PubMed    
    Abstract available

  29. ALHUBAISHY B, Mathes J, Knoll T
    Primary Urothelial Bladder Cancer in a Young Patient: A Case Report and Review of the Literature.
    Cureus. 2021;13:e15864.
    PubMed    
    Abstract available

  30. ZHU J, Huang Z, Zhang M, Wang W, et al
    Erratum: HIF-1alpha promotes ZEB1 expression and EMT in a human bladder cancer lung metastasis animal model.
    Oncol Lett. 2021;22:599.
    PubMed    
    Abstract available

  31. AHDOOT M, Theodorescu D
    Immunotherapy of high risk non-muscle invasive bladder cancer.
    Expert Rev Clin Pharmacol. 2021 Jun 30. doi: 10.1080/17512433.2021.1950531.
    PubMed    
    Abstract available

  32. YAN X, Chen M, Xiao C, Fu J, et al
    Effect of unfolded protein response on the immune infiltration and prognosis of transitional cell bladder cancer.
    Ann Med. 2021;53:1047-1057.
    PubMed    
    Abstract available

  33. MU X, Wu K, Zhu Y, Zhu Y, et al
    Intra-arterial infusion chemotherapy utilizing cisplatin inhibits bladder cancer by decreasing the fi brocytic myeloid-derived suppressor cells in an m6A-dependent manner.
    Mol Immunol. 2021;137:28-40.
    PubMed    
    Abstract available

  34. LU X, Meng J, Zhu J, Zhou Y, et al
    Prognosis stratification and personalized treatment in bladder cancer through a robust immune gene pair-based signature.
    Clin Transl Med. 2021;11:e453.
    PubMed    


  35. ERKOC M, Otunctemur A, Bozkurt M, Can O, et al
    The efficacy and reliability of VI-RADS in determining candidates for repeated transurethral resection in patients with high-risk non-muscle invasive bladder cancer.
    Int J Clin Pract. 2021 Jun 29:e14584. doi: 10.1111/ijcp.14584.
    PubMed    
    Abstract available

  36. MUILWIJK T, Akand M, Van der Aa F, De Coninck V, et al
    Cytokeratin 5 and cytokeratin 20 inversely correlate with tumour grading in Ta non-muscle-invasive bladder cancer.
    J Cell Mol Med. 2021 Jun 29. doi: 10.1111/jcmm.16712.
    PubMed    
    Abstract available

  37. ZHAO R, Shan J, Nie L, Yang X, et al
    The predictive value of the ratio of the product of neutrophils and hemoglobin to lymphocytes in non-muscular invasive bladder cancer patients with postoperative recurrence.
    J Clin Lab Anal. 2021 Jun 29:e23883. doi: 10.1002/jcla.23883.
    PubMed    
    Abstract available

  38. EL GHARIB K, Lilly E, Chebel R
    Checkpoint inhibitors in BCG-unresponsive nonmuscle invasive bladder cancer: can they help spare the bladder?
    Immunotherapy. 2021 Jun 29. doi: 10.2217/imt-2021-0030.
    PubMed    
    Abstract available

  39. CAO B, Li Q, Xu P, Chen W, et al
    Preliminary Exploration of the Application of Vesical Imaging-Reporting and Data System (VI-RADS) in Post-treatment Patients With Bladder Cancer: A Prospective Single-Center Study.
    J Magn Reson Imaging. 2021 Jun 28. doi: 10.1002/jmri.27807.
    PubMed    
    Abstract available

  40. LI R, Zhang J, Gilbert SM, Conejo-Garcia J, et al
    Using oncolytic viruses to ignite the tumour immune microenvironment in bladder cancer.
    Nat Rev Urol. 2021 Jun 28. pii: 10.1038/s41585-021-00483.
    PubMed    
    Abstract available

  41. AIBARA N, Miyata Y, Araki K, Sagara Y, et al
    Detection of Novel Urine Markers Using Immune Complexome Analysis in Bladder Cancer Patients: A Preliminary Study.
    In Vivo. 2021;35:2073-2080.
    PubMed    
    Abstract available

  42. BURNS JE, Hurst CD, Knowles MA, Phillips RM, et al
    The Warburg effect as a therapeutic target for bladder cancers and intratumoral heterogeneity in associated molecular targets.
    Cancer Sci. 2021 Jun 28. doi: 10.1111/cas.15047.
    PubMed    
    Abstract available

  43. GORDETSKY JB, Montgomery KW, Giannico GA, Rais-Bahrami S, et al
    The Significance of Squamous Histology on Clinical Outcomes and PD-L1 Expression in Bladder Cancer.
    Int J Surg Pathol. 2021 Jun 28:10668969211027264. doi: 10.1177/10668969211027264
    PubMed    
    Abstract available

  44. KARIKALAN B, Pasupati T, George SM
    Primary Mucinous Adenocarcinoma of the Urinary Bladder: A Rare Entity.
    West Afr J Med. 2021;38:604-606.
    PubMed    
    Abstract available

  45. ZHENG H, Chen C
    Downregulation of CacyBP by CRISPR/dCas9-KRAB Prevents Bladder Cancer Progression.
    Front Mol Biosci. 2021;8:692941.
    PubMed    
    Abstract available

  46. FU G, Cheng KS, Chen A, Xu Z, et al
    Microfluidic Assaying of Circulating Tumor Cells and Its Application in Risk Stratification of Urothelial Bladder Cancer.
    Front Oncol. 2021;11:701298.
    PubMed    
    Abstract available

  47. ZHANG G, Wu Z, Xu L, Zhang X, et al
    Deep Learning on Enhanced CT Images Can Predict the Muscular Invasiveness of Bladder Cancer.
    Front Oncol. 2021;11:654685.
    PubMed    
    Abstract available

  48. CAO C, Fu Z, Liu Y, Zhou A, et al
    A Muscle-Invasive Bladder Cancer Patient With High Tumor Mutational Burden and RB1 Mutation Achieved Bladder Preservation Following Chemotherapy Combined With Immunotherapy: A Case Report.
    Front Immunol. 2021;12:684879.
    PubMed    
    Abstract available

  49. SUGAYA A, Shimazui T, Kitamura N, Tokita T, et al
    Intra-Abdominal Hypertension-Induced Gastroesophageal Intussusception: A Rare Complication of Transurethral Resection of a Bladder Tumor.
    Am J Case Rep. 2021;22:e930426.
    PubMed    
    Abstract available

  50. FAN L, Yang J, Shen C, Wu Z, et al
    Circ_0030586 inhibits cell proliferation and stemness in bladder cancer by inactivating the ERK signaling via miR-665/NR4A3 axis.
    Acta Histochem. 2021;123:151745.
    PubMed    
    Abstract available

  51. MICHELS CTJ, Wijburg CJ, Hannink G, Witjes JA, et al
    Robot-assisted Versus Open Radical Cystectomy in Bladder Cancer: An Economic Evaluation Alongside a Multicentre Comparative Effectiveness Study.
    Eur Urol Focus. 2021 Jun 23. pii: S2405-4569(21)00166.
    PubMed    
    Abstract available

  52. ISMAEEL N, Patil D, Alemozaffar M, Filson CP, et al
    Palliative care use among bladder cancer patients treated with radical cystectomy.
    Urol Oncol. 2021 Jun 23. pii: S1078-1439(21)00186.
    PubMed    
    Abstract available

  53. OURFALI S, Matillon X, Ricci E, Fassi-Fehri H, et al
    Prognostic Implications of Treatment Delays for Patients with Non-muscle-invasive Bladder Cancer.
    Eur Urol Focus. 2021 Jun 22. pii: S2405-4569(21)00169.
    PubMed    
    Abstract available

  54. HAFIZAR, Hamid ARAH, Saraswati M
    Cystoscopy-assisted laparoscopic partial cystectomy for muscle-invasive bladder cancer: Initial experience in Cipto Mangunkusumo Hospital, Jakarta.
    Int J Surg Case Rep. 2021;84:106083.
    PubMed    
    Abstract available

  55. BIN RIAZ I, Khan AM, Catto JW, Hussain SA, et al
    Bladder cancer: shedding light on the most promising investigational drugs in clinical trials.
    Expert Opin Investig Drugs. 2021 Jun 25. doi: 10.1080/13543784.2021.1948999.
    PubMed    
    Abstract available

  56. MA W, Zhang W, Shen L, Liu J, et al
    Can Smoking Cause Differences in Urine Microbiome in Male Patients With Bladder Cancer? A Retrospective Study.
    Front Oncol. 2021;11:677605.
    PubMed    
    Abstract available

  57. SHORE ND, Palou Redorta J, Robert G, Hutson TE, et al
    Non-muscle-invasive bladder cancer: An overview of potential new treatment options.
    Urol Oncol. 2021 Jun 21. pii: S1078-1439(21)00221.
    PubMed    
    Abstract available

  58. NAKATANI S, Ida M, Wang X, Naito Y, et al
    Oral 5-aminolevulinic acid administration prior to transurethral resection of bladder tumor causes intraoperative hypotension: Propensity score analysis.
    Photodiagnosis Photodyn Ther. 2021;34:102342.
    PubMed    
    Abstract available

  59. OKCU O, Hacihasanoglu E, Koparal MY
    Lymphoepithelioma like carcinoma of the urinary bladder, treated with transurethral resection and intravesical Bacillus Calmette Guerin therapy only: A case report.
    Acta Biomed. 2021;92:e2021031.
    PubMed    
    Abstract available

  60. BUTTY EM, Hahn S, Labato MA
    Presumptive malignant transformation of chronic polypoid cystitis into an apical transitional cell carcinoma without BRAF mutation in a young female dog.
    J Vet Intern Med. 2021;35:1551-1557.
    PubMed    
    Abstract available

  61. PAGLIARONE AC, Castaneda ED, Santana JPP, de Oliveira CAB, et al
    Mitochondrial heat shock protein mortalin as potential target for therapies based on oxidative stress.
    Photodiagnosis Photodyn Ther. 2021;34:102256.
    PubMed    
    Abstract available

  62. PATEL NH, Miranda G, Cai J, Desai M, et al
    Robotic Radical Cystectomy Outcomes after Intervention for Prostate Cancer.
    J Endourol. 2021;35:633-638.
    PubMed    
    Abstract available

  63. ABDALLAH MM, Wahbbah MA, Selem M, Abdou AG, et al
    Correlation between immunohistochemical expression of Ki-67and P63 and aggressiveness of urinary bladder urothelial carcinoma.
    J Immunoassay Immunochem. 2021;42:188-201.
    PubMed    
    Abstract available

  64. YANG Z, Shen Z, Jin D, Zhang N, et al
    Mutations of METTL3 predict response to neoadjuvant chemotherapy in muscle-invasive bladder cancer.
    J Clin Transl Res. 2021;7:386-413.
    PubMed    
    Abstract available

  65. ZHOU R, Liang J, Tian H, Chen Q, et al
    Development of a Ferroptosis-Related lncRNA Signature to Predict the Prognosis and Immune Landscape of Bladder Cancer.
    Dis Markers. 2021;2021:1031906.
    PubMed    
    Abstract available

  66. WU Y, Liu Z, Wei X, Feng H, et al
    Identification of the Functions and Prognostic Values of RNA Binding Proteins in Bladder Cancer.
    Front Genet. 2021;12:574196.
    PubMed    
    Abstract available

  67. SHAN L, Liu W, Zhan Y
    LncRNA HAND2-AS1 exerts anti-oncogenic effects on bladder cancer via restoration of RARB as a sponge of microRNA-146.
    Cancer Cell Int. 2021;21:361.
    PubMed    
    Abstract available

  68. WANG N
    Editorial for "Investigation of Synthetic MRI Applied in the Evaluation of the Tumor Grade of Bladder Cancer".
    J Magn Reson Imaging. 2021 Jul 8. doi: 10.1002/jmri.27826.
    PubMed    


  69. XU S, Cao P, Wang K, Wu T, et al
    Clinical outcomes of reresection in patients with high-risk nonmuscle-invasive bladder cancer treated with en bloc transurethral resection: a retrospective study with a 1-year follow-up.
    J Endourol. 2021 Jul 8. doi: 10.1089/end.2021.0008.
    PubMed    
    Abstract available

  70. CAI Z, Hu J, Othmane B, Li H, et al
    Effects of Fibrin Clot Inhibitors and Statins on the Intravesical Bacille Calmette-Guerin Therapy for Bladder Cancer: A Systematic Review and Meta-Analysis.
    Front Oncol. 2021;11:614041.
    PubMed    
    Abstract available

  71. SANGANI V, Pokal M, Balla M, Merugu GP, et al
    Pembrolizumab related Guillain barre syndrome, a rare presentation in a patient with a history of lupus and bladder cancer.
    J Community Hosp Intern Med Perspect. 2021;11:388-392.
    PubMed    
    Abstract available

  72. JIANG L, Wang Y, Tang H, Li X, et al
    CircCA12 Promotes Malignant Process via Sponging miR-1184 and Upregulating RAS Family in Bladder Cancer.
    Front Genet. 2021;12:663982.
    PubMed    
    Abstract available

  73. ARAGON-CHING JB
    Pembrolizumab use in bladder cancer: a tale of two trials.
    Nat Rev Urol. 2021 Jul 6. pii: 10.1038/s41585-021-00499.
    PubMed    


  74. HAJJAR M, Rezazadeh A, Naja F, Kardoust Parizi M, et al
    Association of the Healthy Nordic Food Index with risk of bladder cancer: a case-control study.
    Eur J Clin Nutr. 2021 Jul 6. pii: 10.1038/s41430-021-00971.
    PubMed    
    Abstract available

  75. OK S, Seo H, Park Y, Kim J, et al
    Curative resection of bladder cancer pancreas head metastasis.
    Ann Hepatobiliary Pancreat Surg. 2021;25.
    PubMed    
    Abstract available

  76. XIE S, Zhao Z, Feng B, Zhang S, et al
    A comparative study of perioperative and survival outcomes of robot-assisted radical cystectomy in patients over 80 and under 80 years old.
    World J Surg Oncol. 2021;19:202.
    PubMed    
    Abstract available

  77. OTT OJ
    [Moderate hypofractionated radiotherapy for bladder cancer-a new standard of care?]
    Strahlenther Onkol. 2021 Jul 6. pii: 10.1007/s00066-021-01804.
    PubMed    


  78. OHADIAN MOGHADAM S, Abbasi B, Nowroozi A, Amini E, et al
    A possible protective role for Bacillus Calmette-Guerin therapy in urinary bladder cancer in the era of COVID-19: a brief report.
    Clin Exp Vaccine Res. 2021;10:191-195.
    PubMed    
    Abstract available

  79. CHEN S, Jiang L, Zhang E, Hu S, et al
    A Novel Nomogram Based on Machine Learning-Pathomics Signature and Neutrophil to Lymphocyte Ratio for Survival Prediction of Bladder Cancer Patients.
    Front Oncol. 2021;11:703033.
    PubMed    
    Abstract available

  80. WANG W, Liu J, Liu L
    Development and Validation of a Prognostic Model for Predicting Overall Survival in Patients With Bladder Cancer: A SEER-Based Study.
    Front Oncol. 2021;11:692728.
    PubMed    
    Abstract available

  81. TIAN Z, Meng L, Wang X, Diao T, et al
    Predictive Nomogram and Risk Factors for Lymph Node Metastasis in Bladder Cancer.
    Front Oncol. 2021;11:690324.
    PubMed    
    Abstract available

  82. YAN X, Wu HH, Chen Z, Du GW, et al
    Construction and Validation of an Autophagy-Related Prognostic Signature and a Nomogram for Bladder Cancer.
    Front Oncol. 2021;11:632387.
    PubMed    
    Abstract available

  83. YANG K, Shen J, Tan FQ, Zheng XY, et al
    Antitumor Activity of Small Activating RNAs Induced PAWR Gene Activation in Human Bladder Cancer Cells.
    Int J Med Sci. 2021;18:3039-3049.
    PubMed    
    Abstract available

  84. XIAO C, Wang Y, Hua M, Zhang W, et al
    Complete transperitoneal laparoscopic nephroureterectomy in a single position for upper urinary tract urothelial carcinoma and comparative outcomes.
    World J Surg Oncol. 2021;19:195.
    PubMed    
    Abstract available

  85. WIGNALL D, Sawant R, Gkentzis A, Lee L, et al
    An unusual presentation of synchronous bladder metastases from an oesophageal adenocarcinoma.
    Ann R Coll Surg Engl. 2021;103:e227-e230.
    PubMed    
    Abstract available

  86. XIE H, Chun FK, Rutz J, Blaheta RA, et al
    Sulforaphane Impact on Reactive Oxygen Species (ROS) in Bladder Carcinoma.
    Int J Mol Sci. 2021;22.
    PubMed    
    Abstract available

  87. SHENG F, Chen KX, Liu J, Li JX, et al
    Chromium (VI) promotes EMT by regulating FLNA in BLCA.
    Environ Toxicol. 2021;36:1694-1701.
    PubMed    
    Abstract available

  88. OZER MS, Yildiz HA, Incir C, Deger MD, et al
    Urinary microbiota; Which non-invasive urine collection method should we use?
    Int J Clin Pract. 2021;75:e14193.
    PubMed    
    Abstract available

  89. MEKA VM, Wankhar B, Ojili V, Batchala PP, et al
    Papillary Urothelial Carcinoma of Urinary Bladder Identified on 18F-Fluciclovine PET/CT.
    Clin Nucl Med. 2021 Mar 16. pii: 00003072-900000000-96157.
    PubMed    
    Abstract available

  90. HUANG RSP, Haberberger J, Harries L, Severson E, et al
    Clinicopathologic and Genomic Characterization of PD-L1 Positive Urothelial Carcinomas.
    Oncologist. 2021;26:375-382.
    PubMed    
    Abstract available

  91. MIURA N, Mori K, Laukhtina E, Schuettfort VM, et al
    Prognostic value of the preoperative albumin-globulin ratio in patients with upper urinary tract urothelial carcinoma treated with radical nephroureterectomy: results from a large multicenter international collaboration.
    Jpn J Clin Oncol. 2021;51:1149-1157.
    PubMed    
    Abstract available

  92. BROWN JT, Liu Y, Shabto JM, Martini DJ, et al
    Baseline Modified Glasgow Prognostic Score Associated with Survival in Metastatic Urothelial Carcinoma Treated with Immune Checkpoint Inhibitors.
    Oncologist. 2021;26:397-405.
    PubMed    
    Abstract available

  93. LAI S, Long X, Wu P, Liu J, et al
    Developing a nomogram for predicting intravesical recurrence after radical nephroureterectomy: a retrospective cohort study of mainland Chinese patients.
    Jpn J Clin Oncol. 2021;51:1132-1141.
    PubMed    
    Abstract available

  94. LU Y, Sun J, Wang Y
    Acute urinary retention with a missed bladder neck leiomyoma.
    Int Urogynecol J. 2021;32:1321-1324.
    PubMed    


  95. XU G, Lu Y
    Optimal Time Point for 68Ga-PSMA-11 PET/CT Imaging in the Assessment of Suspected Metastatic Prostate Cancer in the Bladder of Postprostatectomy Patient.
    Clin Nucl Med. 2021 Feb 9. pii: 00003072-900000000-96219.
    PubMed    
    Abstract available

  96. ROJAS PA, Gonzalez C, Mendez GP, Majerson A, et al
    Bladder squamous cell carcinoma in a pregnant woman: case report and review of the literature.
    BMC Urol. 2021;21:4.
    PubMed    
    Abstract available

  97. ZENG S, Ou H, Gao Z, Zhang J, et al
    HCPT-peptide prodrug with tumor microenvironment -responsive morphology transformable characteristic for boosted bladder tumor chemotherapy.
    J Control Release. 2021;330:715-725.
    PubMed    
    Abstract available

  98. MIHAI IM, Olteanu GE, Herman D, Anderco D, et al
    Analysis of Tumor Depth Invasion With Anti-Smoothelin Antibody in Equivocal Transurethral Resection of Urinary Bladder Tumor Surgical Specimens.
    Int J Surg Pathol. 2021;29:54-63.
    PubMed    
    Abstract available

  99. BANERJEE S, Semper K, Skarparis K, Naisby J, et al
    Patient perspectives of vigorous intensity aerobic interval exercise prehabilitation prior to radical cystectomy: a qualitative focus group study.
    Disabil Rehabil. 2019 Aug 14:1-8. doi: 10.1080/09638288.2019.1651907.
    PubMed    
    Abstract available

  100. CHEN MK, Zhou JH, Wang P, Ye YL, et al
    BMI1 activates P-glycoprotein via transcription repression of miR-3682-3p and enhances chemoresistance of bladder cancer cell.
    Aging (Albany NY). 2021;13.
    PubMed    
    Abstract available

  101. BABOUDJIAN M, Tadrist A, Lechevallier E
    Response to Editorial Comment: "Primary Complete Transurethral Resection of Bladder Tumor Using Photodynamic Diagnosis for High-risk Nonmuscle Invasive Bladder Cancer: Is a Restaging Photodynamic Transurethral Resection Really Necessary?" by Tadrist e
    J Endourol. 2021;35:1049-1050.
    PubMed    


  102. SLOVACEK H, Zhuo J, Taylor JM
    Approaches to Non-Muscle-Invasive Bladder Cancer.
    Curr Oncol Rep. 2021;23:105.
    PubMed    
    Abstract available

  103. WANG Z, Han C, Xu Y, Yu X, et al
    The role of prostate-specific antigen and multiparametric magnetic resonance imaging in the diagnosis of granulomatous prostatitis induced by intravesical Bacillus Calmette-Guerin vaccine therapy in patients with nonmuscle invasive bladder cancer.
    J Cancer Res Ther. 2021;17:625-629.
    PubMed    
    Abstract available

  104. TZELVES L, Xenou D, Skolarikos A, Varkarakis I, et al
    Association of obesity and other anthropometric characteristics with bladder cancer risk: a systematic review and meta-analysis of longitudinal cohort studies.
    J BUON. 2021;26:1040-1055.
    PubMed    
    Abstract available

  105. GOKYER A, Kucukarda A, Kostek O, Sayin S, et al
    The relation between tissue galectin-3 level and platinum resistance in neoadjuvant bladder cancer treatment.
    J BUON. 2021;26:1034-1039.
    PubMed    
    Abstract available

  106. CHEN H, Liu Y, Cao C, Xi H, et al
    CYR61 as a potential biomarker for the preoperative identification of muscle-invasive bladder cancers.
    Ann Transl Med. 2021;9:761.
    PubMed    
    Abstract available

  107. WANG R, Zheng Z, Mao S, Zhang W, et al
    Construction and Validation of a Novel Eight-Gene Risk Signature to Predict the Progression and Prognosis of Bladder Cancer.
    Front Oncol. 2021;11:632459.
    PubMed    
    Abstract available

  108. LAUKHTINA E, Mori K, D Andrea D, Moschini M, et al
    Incidence, risk factors and outcomes of urethral recurrence after radical cystectomy for bladder cancer: A systematic review and meta-analysis.
    Urol Oncol. 2021 Jul 12. pii: S1078-1439(21)00267.
    PubMed    
    Abstract available

  109. HIRANO S, Matsumoto K, Shiono Y, Nakamura M, et al
    [Clinicopathological Characteristics of Adolescent and Young-Adult Patients with Bladder Cancer].
    Hinyokika Kiyo. 2021;67:221-224.
    PubMed    
    Abstract available

  110. CHRYSOSTOMOU S, Roy R, Prischi F, Thamlikitkul L, et al
    Repurposed floxacins targeting RSK4 prevent chemoresistance and metastasis in lung and bladder cancer.
    Sci Transl Med. 2021;13.
    PubMed    
    Abstract available

  111. SCHULZ GB, Todorova R, Braunschweig T, Rodler S, et al
    PD-L1 expression in bladder cancer: Which scoring algorithm in what tissue?
    Urol Oncol. 2021 Jul 11. pii: S1078-1439(21)00260.
    PubMed    
    Abstract available

  112. WEYERER V, Stoehr R, Bertz S, Lange F, et al
    Prognostic impact of molecular muscle-invasive bladder cancer subtyping approaches and correlations with variant histology in a population-based mono-institutional cystectomy cohort.
    World J Urol. 2021 Jul 14. pii: 10.1007/s00345-021-03788.
    PubMed    
    Abstract available

  113. HAO H, Chen H, Xie L, Liu H, et al
    YKL-40 promotes invasion and metastasis of bladder cancer by regulating epithelial mesenchymal transition.
    Ann Med. 2021;53:1169-1177.
    PubMed    
    Abstract available

  114. ZHU J, Zhang F
    Circular RNA VANGL1 knockdown suppressed viability, promoted apoptosis, and increased doxorubicin sensitivity through targeting miR-145-5p to regulate SOX4 in bladder cancer cells.
    Open Med (Wars). 2021;16:1010-1021.
    PubMed    
    Abstract available

  115. FERRO M, Baba DF, de Cobelli O, Musi G, et al
    Neutrophil percentage-to-albumin ratio predicts mortality in bladder cancer patients treated with neoadjuvant chemotherapy followed by radical cystectomy.
    Future Sci OA. 2021;7:FSO709.
    PubMed    
    Abstract available

  116. SPASOVA V, Mladenov B, Rangelov S, Hammoudeh Z, et al
    Clinical impact of copy number variation changes in bladder cancer samples.
    Exp Ther Med. 2021;22:901.
    PubMed    
    Abstract available

  117. CHEN M, Nie Z, Cao H, Gao Y, et al
    Rac3 Expression and its Clinicopathological Significance in Patients With Bladder Cancer.
    Pathol Oncol Res. 2021;27:598460.
    PubMed    
    Abstract available

  118. JEONG H, Oh HE, Kim H, Lee JH, et al
    Upregulation of Fatty Acid Transporters is Associated With Tumor Progression in Non-Muscle-Invasive Bladder Cancer.
    Pathol Oncol Res. 2021;27:594705.
    PubMed    
    Abstract available

  119. MEZA L, Salgia NJ, Patel KC, Pal SK, et al
    Learning from BISCAY: The future of biomarker-based trial design in bladder cancer.
    Cancer Cell. 2021;39:910-912.
    PubMed    
    Abstract available

  120. OZGUL HA, Altay C, Basara Akin I, Bozkurt O, et al
    [Evaluation of solid pulmonary nodules in patients with bladder cancer with computed tomography based texture analysis method: Is it possible to differentiate metastatic - non-metastatic nodules?]
    Tuberk Toraks. 2021;69:227-236.
    PubMed    
    Abstract available

  121. JENSEN JB
    The devil is in the selected details: second-look resection in T1 bladder cancer.
    Scand J Urol. 2021 Jul 13:1. doi: 10.1080/21681805.2021.1948099.
    PubMed    


  122. ZUBKOV AY, Nuriev IR, Sitdykova ME
    [Improvement of oncologic results of transurethral resection in the treatment of non-muscle-invasive bladder cancer].
    Urologiia. 2021;:110-113.
    PubMed    
    Abstract available

  123. KOMYAKOV BK, Sergeev AV, Fadeev VA, Al-Attar TH, et al
    [Long-term results of radical surgery treatment of patients with bladder cancer].
    Urologiia. 2021;:104-109.
    PubMed    
    Abstract available

  124. GHORBANI H, Zarifmahmoudi L, Sadeghi R, Soltani S, et al
    Bowel visualization on the lymphoscintigraphy images of a bladder cancer patient due to inadvertent injection of the tracer in the rectal wall.
    Asia Ocean J Nucl Med Biol. 2021;9:177-179.
    PubMed    
    Abstract available

  125. JANEV A, Ramuta TZ, Tratnjek L, Sardoc Z, et al
    Detrimental Effect of Various Preparations of the Human Amniotic Membrane Homogenate on the 2D and 3D Bladder Cancer In vitro Models.
    Front Bioeng Biotechnol. 2021;9:690358.
    PubMed    
    Abstract available

  126. DONG Y, Ma WM, Shi ZD, Zhang ZG, et al
    Role of NRP1 in Bladder Cancer Pathogenesis and Progression.
    Front Oncol. 2021;11:685980.
    PubMed    
    Abstract available

  127. LUO C, Lei T, Zhao M, Meng Q, et al
    The Role of NPM1 in the Invasion and Migration of Drug Resistant Bladder Cancer.
    Urol J. 2021 Jul 6. pii: 6087. doi: 10.22037/uj.v18i.6087.
    PubMed    
    Abstract available

  128. XU X, Xie B, Li S, Wang S, et al
    Association of dietary tomato intake with bladder cancer risk in a prospective cohort of 101,683 individuals with 12.5 years of follow-up.
    Aging (Albany NY). 2021;13.
    PubMed    
    Abstract available

  129. SHEN C, Zhou K, Wang W, Zhang Y, et al
    The prognostic value of preoperative serum albumin in patients with bladder urothelial carcinoma undergoing transurethral resection of bladder tumor: A prospective cohort study.
    Medicine (Baltimore). 2021;100:e26548.
    PubMed    
    Abstract available

  130. ERMAN A, Kamensek U, Dragin Jerman U, Pavlin M, et al
    How Cancer Cells Invade Bladder Epithelium and Form Tumors: The Mouse Bladder Tumor Model as a Model of Tumor Recurrence in Patients.
    Int J Mol Sci. 2021;22.
    PubMed    
    Abstract available

  131. LOU Y, Ma C, Liu Z, Shi J, et al
    Antimony exposure promotes bladder tumor cell growth by inhibiting PINK1-Parkin-mediated mitophagy.
    Ecotoxicol Environ Saf. 2021;221:112420.
    PubMed    
    Abstract available

  132. ZENGIN ZB, Meza L, Pal SK, Grivas P, et al
    Chemoimmunotherapy in urothelial cancer: concurrent or sequential?
    Lancet Oncol. 2021;22:894-896.
    PubMed    


  133. POWLES T, Csoszi T, Ozguroglu M, Matsubara N, et al
    Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial.
    Lancet Oncol. 2021;22:931-945.
    PubMed    
    Abstract available

  134. GEORGE S, Bell EJ, Zheng Y, Kim R, et al
    The Impact of Adverse Events on Health Care Resource Utilization, Costs, and Mortality Among Patients Treated with Immune Checkpoint Inhibitors.
    Oncologist. 2021;26:e1205-e1215.
    PubMed    
    Abstract available

  135. TSAI CW, Chang WS, Xu Y, Huang M, et al
    Associations of genetically predicted circulating insulin-like growth factor-1 and insulin-like growth factor binding protein-3 with bladder cancer risk.
    Mol Carcinog. 2021 Jul 22. doi: 10.1002/mc.23334.
    PubMed    
    Abstract available

  136. KAO CC, Cheng YC, Yang MH, Cha TL, et al
    Demethoxycurcumin induces apoptosis in HER2 overexpressing bladder cancer cells through degradation of HER2 and inhibiting the PI3K/Akt pathway.
    Environ Toxicol. 2021 Jul 22. doi: 10.1002/tox.23332.
    PubMed    
    Abstract available

  137. ZHANG Q, Hao L, Shen Z, Wang F, et al
    MiR-186-5p suppresses cell migration, invasion, and epithelial mesenchymal transition in bladder cancer by targeting RAB27A/B.
    Environ Toxicol. 2021 Jul 22. doi: 10.1002/tox.23331.
    PubMed    
    Abstract available

  138. TIAN Y, Gao P, Dai D, Chen L, et al
    Circular RNA circSETD3 hampers cell growth, migration, and stem cell properties in bladder cancer through sponging miR-641 to upregulate PTEN.
    Cell Cycle. 2021 Jul 21:1-14. doi: 10.1080/15384101.2021.1954758.
    PubMed    
    Abstract available

  139. DOWER K, Ford A, Sandford M, Doherty A, et al
    Retrospective evaluation of planning margins for patients undergoing radical radiation therapy treatment for bladder cancer using volumetric modulated arc therapy and cone beam computed tomography.
    J Med Radiat Sci. 2021 Jul 20. doi: 10.1002.
    PubMed    
    Abstract available

  140. LEWIS S, Galsky M
    Editorial for "Preliminary Exploration of the Application of Vesical Imaging-Reporting and Data System (VI-RADS) in Post-Treatment Patients with Bladder Cancer: A Prospective Single-Center Study".
    J Magn Reson Imaging. 2021 Jul 19. doi: 10.1002/jmri.27843.
    PubMed    


  141. TU A, Said N, Muddiman DC
    Spatially resolved metabolomic characterization of muscle invasive bladder cancer by mass spectrometry imaging.
    Metabolomics. 2021;17:70.
    PubMed    
    Abstract available

  142. BRANCO EA, Duro R, Brito T, Sarmento A, et al
    Granulomatous Hepatitis Following Intra-Vesical Instillation of Bacillus Calmette-Guerin for Treatment of Bladder Cancer.
    Infect Dis Rep. 2021;13:611-618.
    PubMed    
    Abstract available

  143. AKGUL M, Baykan O, Cagman Z, Ozyurek M, et al
    Gas6 expression and Tyrosine kinase Axl Sky receptors: Their relation with tumor stage and grade in patients with bladder cancer.
    Arch Ital Urol Androl. 2021;93:148-152.
    PubMed    
    Abstract available

  144. MITRAKAS L, Gravas S, Karasavvidou F, Zachos I, et al
    Endothelin-1 indicates unfavorable prognosis in primary high-grade non-muscle-invasive urothelial bladder cancer.
    Arch Ital Urol Androl. 2021;93:143-147.
    PubMed    
    Abstract available

  145. POLINENI P, Ashack L, Kalapurakal J, Morgans A, et al
    Trimodality Treatment for Muscle-Invasive Bladder Cancer: An Institutional Experience.
    Adv Radiat Oncol. 2021;6:100718.
    PubMed    
    Abstract available

  146. CHE X, Zhan J, Zhao F, Zhong Z, et al
    Oridonin Promotes Apoptosis and Restrains the Viability and Migration of Bladder Cancer by Impeding TRPM7 Expression via the ERK and AKT Signaling Pathways.
    Biomed Res Int. 2021;2021:4340950.
    PubMed    
    Abstract available

  147. WEN J, Yang T, Mallouk N, Zhang Y, et al
    Urinary Exosomal CA9 mRNA as a Novel Liquid Biopsy for Molecular Diagnosis of Bladder Cancer.
    Int J Nanomedicine. 2021;16:4805-4811.
    PubMed    
    Abstract available

  148. YANG C, Mou Z, Wu S, Ou Y, et al
    High-throughput sequencing identified circular RNA circUBE2K mediating RhoA associated bladder cancer phenotype via regulation of miR-516b-5p/ARHGAP5 axis.
    Cell Death Dis. 2021;12:719.
    PubMed    
    Abstract available

  149. ZHANG F, Wu H
    MiR-599 targeting TOP2A inhibits the malignancy of bladder cancer cells.
    Biochem Biophys Res Commun. 2021;570:154-161.
    PubMed    
    Abstract available

  150. SHAN G, Zhou X, Gu J, Zhou D, et al
    Correction to: Downregulated exosomal microRNA-148b-3p in cancer associated fibroblasts enhance chemosensitivity of bladder cancer cells by downregulating the Wnt/beta-catenin pathway and upregulating PTEN.
    Cell Oncol (Dordr). 2021 Jul 20. pii: 10.1007/s13402-021-00615.
    PubMed    


  151. ZHANG F, Wang X, Hu H, Yang Y, et al
    A hypoxia related long non-coding RNA signature could accurately predict survival outcomes in patients with bladder cancer.
    Bioengineered. 2021;12:3802-3823.
    PubMed    
    Abstract available

  152. KIM IH, Lee HJ
    Perioperative Systemic Treatment for Muscle-Invasive Bladder Cancer: Current Evidence and Future Perspectives.
    Int J Mol Sci. 2021;22.
    PubMed    
    Abstract available

  153. FERRO M, Lucarelli G, de Cobelli O, Dolce P, et al
    A risk-group classification model in patients with bladder cancer under neoadjuvant cisplatin-based combination chemotherapy.
    Future Oncol. 2021 Jul 19. doi: 10.2217/fon-2020-1298.
    PubMed    
    Abstract available

  154. CHOU KY, Chen PC, Chang AC, Tsai TF, et al
    Attenuation of chloroquine and hydroxychloroquine on the invasive potential of bladder cancer through targeting matrix metalloproteinase 2 expression.
    Environ Toxicol. 2021 Jul 19. doi: 10.1002/tox.23328.
    PubMed    
    Abstract available

  155. WANG Z, Wang X, Wang Y, Tang S, et al
    Transcriptomic Analysis of Gene Networks Regulated by U11 Small Nuclear RNA in Bladder Cancer.
    Front Genet. 2021;12:695597.
    PubMed    
    Abstract available

  156. BESSA A, Bosco C, Cahill F, Russell B, et al
    Designing a Pragmatic Intervention to Help Improve the Bladder Cancer Patient Experience.
    Inquiry. 2021;58:469580211030217.
    PubMed    
    Abstract available

  157. KOBAYASHI G, Takayanagi A, Shindo T, Hashimoto K, et al
    [A Case of Diagnosed Lynch Syndrome in a Patient with Ureteral Cancer].
    Hinyokika Kiyo. 2021;67:229-232.
    PubMed    
    Abstract available

  158. BANCHEREAU R, Leng N, Zill O, Sokol E, et al
    Molecular determinants of response to PD-L1 blockade across tumor types.
    Nat Commun. 2021;12:3969.
    PubMed    
    Abstract available

  159. DETTI B, Sardaro A, Maragna V, Mariotti M, et al
    Radiotherapy is effective in the management of rare penile metastases: Two case reports.
    Cancer Radiother. 2021;25:480-483.
    PubMed    
    Abstract available

  160. BALLAS LK, Navarro S, Luo C, Fossum CC, et al
    Disparities in male versus female oncologic outcomes following bladder preservation: A population-based cohort study.
    Cancer Med. 2021;10:3004-3012.
    PubMed    
    Abstract available

  161. BUSZEK SM, Ludmir EB, Grosshans DR, McAleer MF, et al
    Disease Control and Patterns of Failure After Proton Beam Therapy for Rhabdomyosarcoma.
    Int J Radiat Oncol Biol Phys. 2021;109:718-725.
    PubMed    
    Abstract available

  162. STURARO G, Tasso A, Menilli L, Di Liddo R, et al
    4,6,4'-Trimethylangelicin Photoactivated by Blue Light Might Represent an Interesting Option for Photochemotherapy of Non-Invasive Bladder Carcinoma: An In Vitro Study on T24 Cells.
    Biomolecules. 2021;11.
    PubMed    
    Abstract available

  163. LAUKHTINA E, Pradere B, Mori K, Schuettfort VM, et al
    Catalog of prognostic tissue-based biomarkers in patients treated with neoadjuvant systemic therapy for urothelial carcinoma of the bladder: a systematic review.
    Urol Oncol. 2021;39:180-190.
    PubMed    
    Abstract available

  164. AMANO N, Matsumoto K, Shimizu Y, Nakamura M, et al
    High HNRNPA3 expression is associated with lymph node metastasis and poor prognosis in patients treated with radical cystectomy.
    Urol Oncol. 2021;39:196.
    PubMed    
    Abstract available

  165. POSADA CALDERON L, Al Hussein Al Awamlh B, Shoag J, Patel N, et al
    The role of surgical experience in patient selection, surgical quality, and outcomes in robot-assisted radical cystectomy.
    Urol Oncol. 2021;39:6-12.
    PubMed    
    Abstract available

  166. GRIGG CM, Livasy C, He J, Hartman A, et al
    Human epidermal growth factor receptor 2 overexpression is frequently discordant between primary and metastatic urothelial carcinoma and is associated with intratumoral human epidermal growth factor receptor 2 heterogeneity.
    Hum Pathol. 2021;107:96-103.
    PubMed    
    Abstract available

  167. YANG R, Du Y, Weng X, Chen Z, et al
    Automatic recognition of bladder tumours using deep learning technology and its clinical application.
    Int J Med Robot. 2021;17:e2194.
    PubMed    
    Abstract available

  168. KARDOUST PARIZI M, Margulis V, Compe Rat E, Shariat SF, et al
    The value and limitations of urothelial bladder carcinoma molecular classifications to predict oncological outcomes and cancer treatment response: A systematic review and meta-analysis.
    Urol Oncol. 2021;39:15-33.
    PubMed    
    Abstract available

  169. LOUGHLIN KR
    Relentlessly make yourself obsolete: Robot-assisted radical cystectomy, the emerging standard of care.
    Urol Oncol. 2021;39:13-14.
    PubMed    


  170. SMITH AB, Samuel CA, McCabe SD, Deal A, et al
    Feasibility and delivery of patient-reported outcomes in clinical practice among racially diverse bladder and prostate cancer patients.
    Urol Oncol. 2021;39:77.
    PubMed    
    Abstract available

  171. DRAKAKI A, Pantuck A, Mhatre SK, Dhillon PK, et al
    "Real-world" outcomes and prognostic indicators among patients with high-risk muscle-invasive urothelial carcinoma.
    Urol Oncol. 2021;39:76.
    PubMed    
    Abstract available

  172. JAMAL A, Shahid I, Naveed Shahid M, Saleh Alshmemri M, et al
    Human Papillomavirus, MicroRNA and their Role in Cervical Cancer Progression, Diagnosis and Treatment Response: A Comprehensive Review.
    Pak J Biol Sci. 2020;23:977-988.
    PubMed    
    Abstract available

  173. ZHOU Z, Gao Z, Wu J, Cui Y, et al
    Safety and efficacy of bipolar versus monopolar transurethral resection of bladder tumor: a systematic review and meta-analysis.
    World J Urol. 2021;39:2249-2250.
    PubMed    


  174. ZHU MMT, Burugu S, Gao D, Yu J, et al
    Evaluation of glucocorticoid-induced TNF receptor (GITR) expression in breast cancer and across multiple tumor types.
    Mod Pathol. 2020 Apr 29. pii: 10.1038/s41379-020-0550.
    PubMed    
    Abstract available

  175. SHARMA G, Sharma AP, Mavuduru RS, Bora GS, et al
    Safety and efficacy of bipolar versus monopolar transurethral resection of bladder tumor: a systematic review and meta-analysis.
    World J Urol. 2021;39:377-387.
    PubMed    
    Abstract available

  176. CHAN E, Garg K, Stohr BA
    Integrated immunohistochemical and molecular analysis improves diagnosis of high-grade carcinoma in the urinary bladder of patients with prior radiation therapy for prostate cancer.
    Mod Pathol. 2020 Apr 20. pii: 10.1038/s41379-020-0543.
    PubMed    
    Abstract available

  177. BEANO H, He J, Hensel C, Worrilow W, et al
    Safety of decreasing ureteral stent duration following radical cystectomy.
    World J Urol. 2021;39:473-479.
    PubMed    
    Abstract available

  178. FOSSUM CC, Xiong Y, Magliocco A, Daneshmand S, et al
    Role of Ki-67, MRE11, and PD-L1 as Predictive Biomarkers for Recurrence Pattern in Muscle-invasive Bladder Cancer.
    Anticancer Res. 2021;41:3851-3857.
    PubMed    
    Abstract available

  179. MUKAE Y, Ito H, Miyata Y, Araki K, et al
    Ceruloplasmin Levels in Cancer Tissues and Urine Are Significant Biomarkers of Pathological Features and Outcome in Bladder Cancer.
    Anticancer Res. 2021;41:3815-3823.
    PubMed    
    Abstract available

  180. MASILAMANI AP, Fischer A, Schultze-Seemann S, Kuckuck I, et al
    Epidermal Growth Factor Based Targeted Toxin for the Treatment of Bladder Cancer.
    Anticancer Res. 2021;41:3741-3746.
    PubMed    
    Abstract available

  181. LAWLER C, Gu L, Howard LE, Branche B, et al
    The impact of the social construct of race on outcomes among bacille Calmette-Guerin-treated patients with high-risk non-muscle-invasive bladder cancer in an equal-access setting.
    Cancer. 2021 Jul 8. doi: 10.1002/cncr.33792.
    PubMed    
    Abstract available

  182. WULLWEBER A, Strick R, Lange F, Sikic D, et al
    Bladder Tumor Subtype Commitment Occurs in Carcinoma In Situ Driven by Key Signaling Pathways Including ECM Remodeling.
    Cancer Res. 2021;81:1552-1566.
    PubMed    
    Abstract available

  183. TEO MY, Rosenberg JE
    NECTIN4 heterogeneity and molecular diversity in bladder cancers: deconstructing the activity of an antibody-drug conjugate.
    Clin Cancer Res. 2021 Jul 19. pii: 1078-0432.CCR-21-1807.
    PubMed    
    Abstract available

  184. JANSSEN GWB, Ramkumar RR, Lee BH, van der Heijden AG, et al
    Orthotopic urinary diversions after radical cystectomy for bladder cancer: lessons learned last decade.
    Curr Opin Urol. 2021 Jun 25. pii: 00042307-900000000-98856.
    PubMed    
    Abstract available

  185. HU H
    Re: Richard T. Bryan, Wenyu Liu, Sarah J. Pirrie, et al. Comparing an Imaging-guided Pathway with the Standard Pathway for Staging Muscle-invasive Bladder Cancer: Preliminary Data from the BladderPath Study. Eur Urol 2021;80:12-5.
    Eur Urol. 2021 Jun 29. pii: S0302-2838(21)01859.
    PubMed    


  186. KULKARNI GS
    Re: Radical Cystectomy Against Intravesical BCG for High-risk High-grade Nonmuscle Invasive Bladder Cancer: Results from the Randomized Controlled BRAVO-feasibility Study.
    Eur Urol. 2021 Jun 23. pii: S0302-2838(21)01803.
    PubMed    


  187. VAN DOEVEREN T, Nakauma-Gonzalez JA, Mason AS, van Leenders GJLH, et al
    The clonal relation of primary upper urinary tract urothelial carcinoma and paired urothelial carcinoma of the bladder.
    Int J Cancer. 2021;148:981-987.
    PubMed    
    Abstract available

  188. KOIE T, Hashimoto Y, Imai A, Yoneyama T, et al
    Long-term chronological changes in urination status of patients who underwent ileal neobladder reconstruction at a single institution.
    Int Urol Nephrol. 2021;53:275-280.
    PubMed    
    Abstract available

  189. WANG Y, Shen W, Yuan X, Akezhouli S, et al
    A perioperative management to reduce rate of urinary tract infection for patient underwent radical cystectomy with ileal conduit diversion.
    Int Urol Nephrol. 2020 Oct 17. pii: 10.1007/s11255-020-02653.
    PubMed    
    Abstract available

  190. TAKAMATSU K, Matsumoto K, Kikuchi E, Ogihara K, et al
    Can random bladder biopsies be eliminated after bacillus Calmette-Guerin therapy against carcinoma in situ?
    Int Urol Nephrol. 2021;53:465-469.
    PubMed    
    Abstract available

  191. AZEVEDO RM, de Oliveira Carneiro J, da Silva NDF, Athanazio DA, et al
    Bladder venous malformation.
    Int Urol Nephrol. 2021;53:281-282.
    PubMed    


  192. MICHELLE R, Liguori G, Trombetta C
    Antimicrobial Prophylaxis for Postoperative Urinary Tract Infections in Transurethral Resection of Bladder Tumors: A Systematic Review and Meta-analysis. Letter.
    J Urol. 2021 Feb 12:101097JU0000000000001649. doi: 10.1097/JU.0000000000001649.
    PubMed    


  193. SCHOENBERG M, Steinberg G
    Rethinking the Treatment of Recurrent Nonmuscle-Invasive Bladder Cancer.
    J Urol. 2021;206:7-9.
    PubMed    


  194. PIERETTI A, Krasnow R, Drumm M, Gusev A, et al
    Complications and Outcomes of Salvage Cystectomy after Trimodality Therapy.
    J Urol. 2021;206:29-36.
    PubMed    
    Abstract available

  195. WOLDU SL, Ng CK, Loo RK, Slezak JM, et al
    Evaluation of the New American Urological Association Guidelines Risk Classification for Hematuria.
    J Urol. 2021;205:1387-1393.
    PubMed    
    Abstract available

  196. HASHEM A, Abol-Enein H, Laymon M, Abdellutif MM, et al
    A Randomized Trial to Examine the Utility of Mebeverine on the Early Return of Continence Following Orthotopic Bladder Substitution.
    J Urol. 2021;205:1400-1406.
    PubMed    
    Abstract available

  197. MATULEWICZ RS, Basak R, Zambrano I, Dearing BA, et al
    Patterns of Current Cigarette Smoking, Quit Attempts and Cessation Counseling among Survivors of Smoking-Related and Nonsmoking-Related Urological Malignancies: A Nationally Representative Cross-Sectional Analysis.
    J Urol. 2021;205:1444-1451.
    PubMed    
    Abstract available

  198. WYMER KM, Sharma V, Saigal CS, Chamie K, et al
    Cost-Effectiveness Analysis of Pembrolizumab for Bacillus Calmette-Guerin-Unresponsive Carcinoma In Situ of the Bladder.
    J Urol. 2021;205:1326-1335.
    PubMed    
    Abstract available

  199. GAO T, Ji Y
    Long Noncoding RNA LINC00707 Accelerates Tumorigenesis and Progression of Bladder Cancer via Targeting miR-145/CDCA3 Regulatory Loop.
    Urol Int. 2021 Jun 30:1-15. doi: 10.1159/000514388.
    PubMed    
    Abstract available

  200. KAYNAR M, Celik ZE, Altintas E, Batur AF, et al
    Comparison of Two Different Bipolar Energy Resources in Transurethral Resection of Bladder Tumors.
    Urol Int. 2021;105.
    PubMed    
    Abstract available

  201. IZOL V, Deger M, Ozden E, Bolat D, et al
    The Effect of Diagnostic Ureterorenoscopy on Intravesical Recurrence in Patients Undergoing Nephroureterectomy for Primary Upper Tract Urinary Carcinoma.
    Urol Int. 2021;105.
    PubMed    
    Abstract available

  202. YANG C, Lv Z, Li Y
    Reduction of Bladder Volume after BCG Immunotherapy.
    Urol Int. 2021;105.
    PubMed    
    Abstract available

  203. KUPERUS JM, Busman RD, Kuipers SK, Broekhuizen HT, et al
    Comparison of Side Effects and Tolerability Between Intravesical Bacillus Calmette-Guerin, Reduced-Dose BCG, and Gemcitabine for Non-Muscle Invasive Bladder Cancer.
    Urology. 2021 Jul 1. pii: S0090-4295(21)00577.
    PubMed    
    Abstract available

  204. RICHTER LA, Egan J, Alagha EC, Handa VL, et al
    Vaginal Complications after Radical Cystectomy for Bladder Cancer: A Systematic Review.
    Urology. 2021 Jul 17. pii: S0090-4295(21)00656.
    PubMed    
    Abstract available

  205. HERR H, Vertosick EA, Dalbagni G, Cha EK, et al
    Prospective Phase II Study to Evaluate Response to Two Induction Courses (12 intravesical instillations) of BCG Therapy for High-Risk Non-Muscle-Invasive Bladder Cancer.
    Urology. 2021 Jul 15. pii: S0090-4295(21)00642.
    PubMed    
    Abstract available

  206. FU Y, Sun S, Bi J, Kong C, et al
    A novel immune-related gene pair prognostic signature for predicting overall survival in bladder cancer.
    BMC Cancer. 2021;21:810.
    PubMed    
    Abstract available

  207. TANG X, Qian WL, Yan WF, Pang T, et al
    Radiomic assessment as a method for predicting tumor mutation burden (TMB) of bladder cancer patients: a feasibility study.
    BMC Cancer. 2021;21:823.
    PubMed    
    Abstract available

  208. JIANG H, Gu X, Zuo Z, Tian G, et al
    Prognostic value of circulating tumor cells in patients with bladder cancer: A meta-analysis.
    PLoS One. 2021;16:e0254433.
    PubMed    
    Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Bladder Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design:


;